Treatment for Toxoplasma gondii
The treatment for Toxoplasma gondii infection depends critically on the clinical context: pyrimethamine plus sulfadiazine plus folinic acid (leucovorin) is the standard regimen for most active infections, while spiramycin is used specifically for pregnant women without confirmed fetal infection. 1
Treatment by Clinical Scenario
Congenital Toxoplasmosis in Infants
For infants with confirmed or suspected congenital toxoplasmosis, treat for 12 months total with pyrimethamine, sulfadiazine, and folinic acid 1:
Initial intensive phase (first 2-6 months):
- Pyrimethamine: 2 mg/kg/day PO divided BID for 2 days, then 1 mg/kg/day PO daily
- Sulfadiazine: 100 mg/kg/day PO divided BID
- Folinic acid: 10 mg PO three times weekly
The intensive phase should continue for 2 months in asymptomatic infants, but extend to 6 months for symptomatic infants 1.
Continuation phase (to complete 12 months):
- Pyrimethamine: 1 mg/kg/day PO three times weekly
- Sulfadiazine: 100 mg/kg/day PO divided BID
- Folinic acid: 10 mg PO three times weekly
Add prednisone 1 mg/kg/day PO divided BID if CSF protein ≥1 g/dL or severe vision-threatening chorioretinitis (start after 72 hours of anti-Toxoplasma therapy; continue until CSF protein <1 g/dL or chorioretinitis resolves) 1.
Pregnant Women
For pregnant women with acute infection but no confirmed fetal infection:
- Spiramycin 1 g (3 million IU) PO TID (total 3 g or 9 million IU daily) until delivery 1
- Available in the US only through FDA Investigational New Drug process (301-796-1600)
- Spiramycin is not teratogenic and reduces vertical transmission risk
For pregnant women ≥18 weeks gestation with confirmed or suspected fetal infection (positive amniotic fluid PCR, abnormal fetal ultrasound, or acute infection acquired ≥18 weeks) 1:
- Pyrimethamine: 100 mg/day PO divided BID for 2 days, then 50 mg/day PO daily
- Sulfadiazine: 75 mg/kg loading dose PO × 1, then 100 mg/kg/day PO divided BID (maximum 4 g/day)
- Folinic acid: 10-20 mg/day PO daily (during and 1 week after pyrimethamine)
Critical caveat: Pyrimethamine is potentially teratogenic and should not be used before 18 weeks gestation 1, 2.
Older Children with Active Chorioretinitis
Treat for 4-6 weeks total, continuing at least 1-2 weeks after resolution of all signs and symptoms 1:
- Pyrimethamine: 2 mg/kg/day PO divided BID (max 50 mg/day) for 2 days, then 1 mg/kg/day PO daily (max 25 mg/day)
- Sulfadiazine: 75 mg/kg loading dose PO × 1, then 100 mg/kg/day PO divided BID
- Folinic acid: 10-20 mg PO three times weekly
- Prednisone: 1 mg/kg/day divided BID (max 40 mg/day) for severe chorioretinitis, with rapid taper 1
Immunocompromised Adults (Toxoplasmic Encephalitis)
The standard regimen remains pyrimethamine plus sulfadiazine 3, 2:
- Pyrimethamine: Loading dose followed by maintenance dosing
- Sulfadiazine: Standard adult dosing
- Folinic acid: To prevent bone marrow suppression
Alternative regimens when standard therapy is not tolerated 3:
- Trimethoprim-sulfamethoxazole (similar efficacy to pyrimethamine-sulfadiazine)
- Pyrimethamine plus clindamycin (no difference in efficacy but potentially better tolerated)
The cure rate for toxoplasmic encephalitis is approximately 50% with standard therapy, with no statistical difference between pyrimethamine-sulfadiazine, trimethoprim-sulfamethoxazole, or pyrimethamine-clindamycin 4, 3.
Key Clinical Considerations
Folinic acid (leucovorin) is mandatory with pyrimethamine to prevent bone marrow toxicity—never use folic acid, which antagonizes pyrimethamine's antiparasitic effect 1.
Consultation with toxoplasmosis specialists is strongly recommended for all cases, particularly congenital infections. Contact the Palo Alto Medical Foundation Toxoplasma Serology Laboratory or the Toxoplasmosis Center in Chicago 1.
Common pitfall: Pyrimethamine-sulfadiazine has frequent serious side effects including bone marrow suppression, rash, and hepatotoxicity 3, 2. Monitor CBC and liver function regularly.
Prevention in high-risk populations: Trimethoprim-sulfamethoxazole prophylaxis should be considered for severely immunosuppressed patients (transplant recipients, those on targeted immunomodulators like CAR-T therapy or biologics) who are Toxoplasma IgG-positive 5, 6.
Emerging concern: The expanding use of targeted immunotherapies (biologics, small molecules, CAR-T cells) creates new at-risk populations beyond traditional transplant settings, requiring baseline Toxoplasma screening and prophylaxis strategies 5, 6.